Nature Medicine CiteScore 2024-2025 - ResearchHelpDesk - Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine on the basis of its originality, timeliness, interdisciplinary interest and impact on improving human health. Nature Medicine also publishes commissioned content, including News, Reviews and Perspectives, aimed at contextualizing the latest advances in translational and clinical research to reach a wide audience of M.D. and PhD readers. All editorial decisions are made by a team of full-time professional editors. Nature Medicine publishes research that addresses the needs and goals of contemporary medicine. Original research ranges from new concepts in human biology and disease pathogenesis to robust preclinical bases for new therapeutic modalities and drug development to all phases of clinical work, as well as innovative technologies aimed at improving human health. Current areas of interest also include, but are not limited to: Gene and cell therapies Clinical genomics Regenerative medicine High-definition medicine Effects of the environment in human health Artificial intelligence in health care Smart wearable devices Early disease diagnosis Microbiome Aging Nature Medicine also publishes Reviews, Perspectives and other content commissioned from leading scientists in their fields to provide expert and contextualized views of the latest research driving the progress of medicine. The Magazine section is editorially independent and provides topical and timely reporting of upcoming trends affecting medicine, researchers and the general audience.

Artificial Intelligence in Healthcare Diagnosis Market Size, Trends, and Forecast The global artificial intelligence (AI) in healthcare diagnosis market size was valued at USD XXX million in 2025 and is projected to expand at a compound annual growth rate (CAGR) of 5% from 2025 to 2033. The increasing adoption of AI-powered diagnostic tools in healthcare facilities, rising prevalence of chronic diseases, and growing demand for personalized medicine are key factors driving market growth. Technological advancements, such as deep learning and natural language processing, have enabled AI algorithms to analyze vast amounts of medical data, including medical images, electronic health records, and genetic information, with high accuracy. This capability makes AI-powered diagnostic systems invaluable in detecting and diagnosing diseases earlier and more accurately than traditional methods. Additionally, AI algorithms can assist healthcare professionals in making informed treatment decisions, reducing healthcare costs, and improving patient outcomes. Artificial intelligence (AI) is rapidly transforming the healthcare industry, and its impact is particularly significant in the field of diagnosis. AI-powered tools are being used to analyze medical images, identify patterns, and predict outcomes, which is leading to more accurate and timely diagnoses. This is having a major impact on patient care, as it allows doctors to make better decisions and provide more personalized treatment plans. The AI in healthcare diagnosis market is expected to grow from USD 1.5 billion in 2023 to USD 9.4 billion by 2028, at a CAGR of 39.1% during the forecast period. The growth of this market is attributed to the increasing adoption of AI in healthcare, the rising prevalence of chronic diseases, and the growing need for accurate and timely diagnosis. The AI in healthcare diagnosis market is segmented into the following types:

Medical imaging tools, used to analyze medical images and identify patterns. Automated detection systems, used to detect and classify diseases based on medical images. Others, such as natural language processing tools and predictive analytics tools.

The AI in healthcare diagnosis market is also segmented into the following applications:

Hospitals and clinics Diagnostic laboratories Home care Others, such as research and development

The AI in healthcare diagnosis market is concentrated in North America, with the United States being the leading market. Europe is the second largest market, followed by Asia Pacific. The market is expected to grow rapidly in Asia Pacific, due to the increasing adoption of AI in healthcare and the rising prevalence of chronic diseases. Major players in the AI in healthcare diagnosis market include:

Koninklijke Philips N.V. (Netherlands) General Electric Company (United States) Aidoc (Israel) Arterys Inc. (United States) Icometrix (United States) IDx Technologies Inc. (United States) MaxQ AI Ltd. (United Kingdom) Caption Health, Inc. (United States) Zebra Medical Vision Inc. (Israel) Siemens Healthineers AG (Germany)

These companies are investing heavily in research and development, and they are launching new products and services to meet the growing demand for AI in healthcare diagnosis. The AI in healthcare diagnosis market is facing a number of challenges, including the lack of regulatory clarity, the need for large amounts of data, and the potential for bias in AI algorithms. However, the benefits of AI in healthcare diagnosis are significant, and the market is expected to continue to grow rapidly in the coming years.

Report of Artificial Intelligence in the Medical Imaging Market is covering the summarized study of several factors encouraging the growth of the market such as market size, market type, major regions and end user applications. By using the report customer can recognize the several drivers that impact and govern the market. The report is describing the several types of Artificial Intelligence in the Medical Imaging Industry. Factors that are playing the major role for growth of specific type of product category and factors that are motivating the status of the market.

The global medical AI-assisted diagnosis product market is experiencing robust growth, driven by the increasing prevalence of chronic diseases, the demand for improved diagnostic accuracy, and the rising adoption of artificial intelligence in healthcare. The market's Compound Annual Growth Rate (CAGR) is estimated to be around 15% from 2025 to 2033, indicating significant expansion potential. Several key factors are contributing to this growth. Firstly, AI algorithms are demonstrating their ability to analyze medical images (X-rays, CT scans, MRIs) and patient data with greater speed and accuracy than traditional methods, leading to earlier and more effective diagnoses. Secondly, the integration of AI into existing healthcare systems is becoming increasingly streamlined, facilitating wider adoption across hospitals and clinics. Thirdly, regulatory approvals for AI-based diagnostic tools are accelerating, boosting market confidence and investment. However, challenges remain, including concerns about data privacy and security, the need for robust validation and regulatory compliance, and the high initial investment costs associated with implementing AI-based systems. The market is segmented by application (e.g., oncology, cardiology, radiology) and type (e.g., image-based, data-based diagnostic tools), with the image-based segment currently dominating due to its immediate applicability and visible impact. North America and Europe are expected to maintain significant market shares due to their advanced healthcare infrastructure and high adoption rates of new technologies, while Asia Pacific is poised for considerable growth given its burgeoning healthcare sector and rising technological investments. The market is further characterized by a competitive landscape with both established medical device companies and emerging AI technology firms vying for market share. Strategic partnerships and acquisitions are frequent, reflecting the desire for companies to leverage existing capabilities and expand their market reach. Future growth will depend on the continuous improvement of AI algorithms, the development of more user-friendly interfaces, and the effective addressing of ethical and regulatory concerns. The market is also anticipated to benefit from increasing government support for AI research and development in healthcare. As the technology matures and becomes more affordable, its adoption rate will likely accelerate, leading to a wider availability of AI-assisted diagnosis products across various healthcare settings globally. This trend promises to transform the healthcare landscape by improving patient outcomes, reducing healthcare costs, and enhancing the efficiency of diagnostic processes.

The global medical journal market is a dynamic sector characterized by significant growth driven by several key factors. The increasing prevalence of chronic diseases, coupled with the expanding research and development activities in the pharmaceutical and biotechnology industries, fuels the demand for high-quality, peer-reviewed medical publications. Technological advancements, particularly the rise of electronic versions and online access, are transforming the way medical professionals consume information, leading to increased accessibility and broader reach. The market is segmented by application (Research Institutes, Hospitals, Individuals, Others) and type (Paper Version, Electronic Version). While the paper version segment continues to hold a market share, the electronic version demonstrates robust growth, driven by its convenience, cost-effectiveness, and widespread accessibility. Furthermore, the integration of advanced technologies like data analytics and artificial intelligence within medical journals is expected to enhance their value and functionality, further driving market expansion. Key players, including The Lancet, Nature, BMJ, and NEJM Group, are actively shaping market dynamics through innovative publishing models and strategic acquisitions. Geographical distribution reveals significant regional variations, with North America and Europe holding substantial market shares, attributed to robust healthcare infrastructure, extensive research activities, and high per capita healthcare expenditure. However, emerging economies in Asia-Pacific and other regions are exhibiting strong growth potential, driven by increasing healthcare investments and a rising middle class. The market's future trajectory reflects a consistent upward trend, with the compound annual growth rate (CAGR) projected to remain healthy for the forecast period (2025-2033). Restraints such as subscription costs and the need for open access initiatives to ensure broader access to research are prevalent. However, the continued advancement of technology, the escalating demand for evidence-based medicine, and increasing healthcare expenditures are likely to outweigh these challenges, ensuring sustainable growth. The strategic partnerships between publishers, research institutions, and healthcare providers will play a crucial role in shaping the future landscape, fostering collaboration and dissemination of crucial medical knowledge globally. This growth will likely lead to increased competition, encouraging publishers to continuously innovate and enhance the quality and accessibility of their journals.

According to Cognitive Market Research, the global Artificial Intelligence in Drug Discovery market size is USD 815.2 million in 2024 and will expand at a compound annual growth rate (CAGR) of 40.00% from 2024 to 2031.

North America held the major market of more than 40% of the global revenue with a market size of USD 326.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 38.2% from 2024 to 2031.
Europe accounted for a share of over 30% of the global market size of USD 244.56 million.
Asia Pacific held the market of around 23% of the global revenue with a market size of USD 187.50 million in 2024 and will grow at a compound annual growth rate (CAGR) of 42.0% from 2024 to 2031.
Latin America market of more than 5% of the global revenue with a market size of USD 40.76 million in 2024 and will grow at a compound annual growth rate (CAGR) of 39.4% from 2024 to 2031.
Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 16.30 million in 2024 and will grow at a compound annual growth rate (CAGR) of 39.7% from 2024 to 2031.
The services held the highest Artificial Intelligence in Drug Discovery market revenue share in 2024.

Market Dynamics of Artificial Intelligence in Drug Discovery Market

Key Drivers for Artificial Intelligence in Drug Discovery Market

Increasing Demand for Personalized Medicine will Boost the Market Growth

Customised medication, fitting medicines to individual patients in the opinion of their hereditary cosmetics and different elements, is picking up speed because of its capability to develop results further and limit unfavorable impacts. Simulated intelligence assumes an urgent role in this change in outlook by dissecting tremendous datasets enveloping genomics, proteomics, and clinical records. AI calculations filter through this information to recognize examples and connections, supporting the revelation of biomarkers for sickness inference and guessing. Regular language handling empowers the abstraction of significant experiences from unstructured clinical notes and examination writing. By utilizing computer-based intelligence, specialists can foster designated treatments that address the particular sub-atomic qualities of a patient's illness, improving treatment viability and patient outcomes in a period progressively centered around customized medical services.

Growing Complexity of Drug Development Process will Augment the Market Growth

Conventional medication discovery faces difficulties originating from the difficulty of illnesses, high disappointment rates in clinical preliminaries, and rising improvement costs. Simulated intelligence offers inventive answers to assist different phases of medication advancement by outfitting the force of computational calculations and huge information investigation. AI calculations break down different datasets, for example, genomic successions and compound designs, to anticipate drug-target collaborations and distinguish promising competitors. Besides, artificial intelligence-driven models smooth out lead streamlining and harmfulness expectations, lessening the time and assets expected for preclinical testing. By speeding up the speed of medication disclosure and advancing asset assignment, artificial intelligence advancements moderate dangers and improve the productivity of medication improvement.

Restraint Factor for the Artificial Intelligence in Drug Discovery Market

Regulatory Compliance and Ethical Considerations will Hinder the Market Growth

One critical limitation in the Man-made reasoning in the medication discovery market is the test of accomplishing adequate brilliance and picture quality in conservative and compact gadgets. Because of their small size and appreciative power sources, Man-made consciousness in Medication Revelation frequently battles to convey a similar degree of splendor and picture lucidity as bigger, fixed projectors. This impediment can obstruct their viability in brilliantly lit conditions or while projecting onto bigger screens, lessening their common sense for specific applications like proficient introductions or outside occasions. While progressions in Drove and laser projection innovation have further developed brilliance levels in Man-made brainpower in Medication Disclosure, accomplishing great pictures without compromising versatility remains a critical test for makers.

Impact of Covid-19 on the...

The North America artificial intelligence (AI) in healthcare market is experiencing explosive growth, projected to reach $4.62 billion in 2025 and maintain a robust Compound Annual Growth Rate (CAGR) of 26.27% from 2025 to 2033. This expansion is driven by several key factors. The increasing prevalence of chronic diseases necessitates more efficient and accurate diagnostic tools and treatment plans, fueling demand for AI-powered solutions. Furthermore, the rising adoption of electronic health records (EHRs) provides a rich dataset for training AI algorithms, improving their accuracy and efficacy. The development of sophisticated AI technologies like natural language processing (NLP), deep learning, and context-aware processing enables more precise disease prediction, personalized medicine, and drug discovery. Robotic-assisted surgery, virtual nursing assistants, and AI-powered diagnostic tools are rapidly gaining traction, demonstrating the market's versatility and significant impact across the healthcare ecosystem. Significant investments from both public and private sectors are further bolstering innovation and market expansion. However, despite the rapid growth, challenges remain. Data privacy and security concerns are paramount, demanding robust regulatory frameworks and ethical considerations. The high cost of AI implementation and integration within existing healthcare infrastructure can act as a barrier for smaller organizations. Moreover, the need for substantial training datasets and skilled professionals to manage and interpret AI-generated insights pose significant hurdles. Overcoming these challenges requires collaborative efforts between healthcare providers, technology companies, and regulatory bodies to ensure responsible and widespread adoption of AI in healthcare. The market's segmentation across technologies (NLP, deep learning, etc.), applications (drug discovery, diagnostics, etc.), offerings (hardware, software, services), and end-users (providers, payers, patients) reflects its diverse applications and opportunities for growth across the North American landscape, particularly within the United States, Canada, and Mexico. Recent developments include: April 2024: ABOUT Healthcare acquired Edgility, an AI analytics platform that provides prescriptive and predictive analysis for patient progression solutions. This acquisition helped the company to expand its patient capacity offerings., March 2024: NVIDIA Healthcare launched generative AI microservices to foster advancements in medical technology, digital health, and drug discovery. This launch helped healthcare enterprises to take advantage of generative AI.. Key drivers for this market are: Growing Need to Reduce Increasing Healthcare Costs, Technological Advancements; Ability of AI to Improve Patient Outcomes and Growing Importance of AI-assisted Robot Surgery. Potential restraints include: Growing Need to Reduce Increasing Healthcare Costs, Technological Advancements; Ability of AI to Improve Patient Outcomes and Growing Importance of AI-assisted Robot Surgery. Notable trends are: The Medical Imaging and Diagnostics Segment is Anticipated to Register Significant Growth Rate During the Forecast Period.

Nature Medicine Acceptance Rate - ResearchHelpDesk - Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine on the basis of its originality, timeliness, interdisciplinary interest and impact on improving human health. Nature Medicine also publishes commissioned content, including News, Reviews and Perspectives, aimed at contextualizing the latest advances in translational and clinical research to reach a wide audience of M.D. and PhD readers. All editorial decisions are made by a team of full-time professional editors. Nature Medicine publishes research that addresses the needs and goals of contemporary medicine. Original research ranges from new concepts in human biology and disease pathogenesis to robust preclinical bases for new therapeutic modalities and drug development to all phases of clinical work, as well as innovative technologies aimed at improving human health. Current areas of interest also include, but are not limited to: Gene and cell therapies Clinical genomics Regenerative medicine High-definition medicine Effects of the environment in human health Artificial intelligence in health care Smart wearable devices Early disease diagnosis Microbiome Aging Nature Medicine also publishes Reviews, Perspectives and other content commissioned from leading scientists in their fields to provide expert and contextualized views of the latest research driving the progress of medicine. The Magazine section is editorially independent and provides topical and timely reporting of upcoming trends affecting medicine, researchers and the general audience.

CR-AI4SkIN is a public dataset composed of H&E patches extracted from Whole Slide Images. This dataset contains Cutaneous Spindle Cell neoplasms, and the task is to classify WSIs into benign or malignant. The main feature of this dataset is that it has been labeled by ten non-expert annotators.

This repository contains the associated files to replicate the study titled "Annotation Protocol and Crowdsourcing Multiple Instance Learning Classification of Skin Histological Images: The CR-AI4SkIN Dataset", published in the Artificial Intelligence in Medicine journal. For further details on the study and the dataset, please see the published article.

The zipped file 'annotations.zip' contains three .csv files with crowdsourcing annotations. These files provide the train/val/test split as well as label information. The 'GT' column stands for the expert label, 'MV' for the majority vote among non-experts, and 'Marker_X' is the label given by the X-th annotator.

The zipped file 'img.zip' contains the dataset images divided into two sub-directories indicating the source hospital. Each image is associated with its own folder, which is identified using anonymized IDs. Within each folder, we include the extracted patches representing the predicted regions of interest. Note: We did not include 1 image in the training set and another in the test set because the regions of interest were not found/had troubles.

Label Dictionary:

0: Benign 1: Malignant -1: Missing value (e.g., if an annotator did not label that image).

Hospital Dictionary:

HCUV: Hospital Clínico Universitario de Valencia (Valencia Hospital).HUSC: Hospital Universitario San Cecilio (Granada Hospital).

Citation:

If you use this dataset, please cite the following article:

@article{del2023annotation, title={Annotation protocol and crowdsourcing multiple instance learning classification of skin histological images: The CR-AI4SkIN dataset}, author={Del Amor, Rocío and Pérez-Cano, Jose and López-Pérez, Miguel and Terradez, Liria and Aneiros-Fernandez, Jose and Morales, Sandra and Mateos, Javier and Molina, Rafael and Naranjo, Valery}, journal={Artificial Intelligence in Medicine}, volume={145}, pages={102686}, year={2023}, publisher={Elsevier} }

Funding:

This work has received funding from the Spanish Ministry of Economy and Competitiveness through project PID2019-105142RB (AI4SKIN) and Spanish Ministry of Science and Innovation through project PID2022-140189OB, from Horizon 2020, the European Union’s Framework Programme for Research and Innovation, under the grant agreement No. 860627 (CLARIFY), grant B-TIC-324-UGR20 funded by Consejería de Universidad, Investigación e Innovación (Junta de Andalucía) and by “ERDF A way of making Europe”, and GVA through the project INNEST/2021/321 (SAMUEL). The work of Rocío del Amor has been supported by the Spanish Ministry of Universities (FPU20/05263). The work of Miguel López Pérez has been supported by the University of Granada postdoctoral program “Contrato Puente”. The work of Sandra Morales has been co-funded by the Universitat Politècnica de València through the program PAID-10-20.

This study explored the factors influencing patients' willingness to adopt AI-powered personalized medicine. This research found the problems. Integrating AI and personalized medicine has the potential to revolutionize healthcare. However, public trust in AI for healthcare applications remains a challenge. This research examines the factors determining people's views toward using artificial intelligence for predictive analytics in personalized medicine. A cross-sectional design was employed through a survey distributed via Google Forms in April 2024 using purposive sampling. The target respondents included residents of the Jabodetabek area (Jakarta, Bogor, Depok, Tangerang, Bekasi- cities in Indonesia) with prior experience seeking medical consultation or checkups. A total of 267 responses were collected after removing outliers. The study used a Partial Least Squares Structural Equation Modeling (PLS-SEM) approach to analyze the data. The study considered six independent variables: AI knowledge, trust in AI, attitude towards data privacy, personalized medicine expectations, personalized medicine understanding, and perceived risk of discrimination in AI. The dependent variable was the intention to use AI in personalized medicine. It found five of six hypotheses have significant impact.

✅ Nature Medicine Subscription Price - ResearchHelpDesk - Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine on the basis of its originality, timeliness, interdisciplinary interest and impact on improving human health. Nature Medicine also publishes commissioned content, including News, Reviews and Perspectives, aimed at contextualizing the latest advances in translational and clinical research to reach a wide audience of M.D. and PhD readers. All editorial decisions are made by a team of full-time professional editors. Nature Medicine publishes research that addresses the needs and goals of contemporary medicine. Original research ranges from new concepts in human biology and disease pathogenesis to robust preclinical bases for new therapeutic modalities and drug development to all phases of clinical work, as well as innovative technologies aimed at improving human health. Current areas of interest also include, but are not limited to: Gene and cell therapies Clinical genomics Regenerative medicine High-definition medicine Effects of the environment in human health Artificial intelligence in health care Smart wearable devices Early disease diagnosis Microbiome Aging Nature Medicine also publishes Reviews, Perspectives and other content commissioned from leading scientists in their fields to provide expert and contextualized views of the latest research driving the progress of medicine. The Magazine section is editorially independent and provides topical and timely reporting of upcoming trends affecting medicine, researchers and the general audience.

Snapshot img

Artificial Intelligence In Drug Discovery Market Size 2025-2029

The artificial intelligence in drug discovery market size is forecast to increase by USD 4.32 billion at a CAGR of 25.7% between 2024 and 2029.

Artificial Intelligence (AI) is revolutionizing the drug discovery market, offering significant potential for accelerating the development of new therapies. Key growth factors include the availability of funding and strategic partnerships between industry players and tech companies. However, regulatory hurdles pose a challenge, as AI applications in drug discovery must meet stringent regulatory requirements.
Additionally, the use of AI in drug discovery is trending, with its ability to process vast amounts of data and identify potential drug candidates more efficiently than traditional methods. This market analysis report provides an in-depth examination of these factors and their impact on the drug discovery market's growth trajectory. AI's potential to transform the pharmaceutical industry is undeniable, and this report offers valuable insights into the opportunities and challenges associated with its adoption. AI-powered safety monitoring systems ensure that drugs meet professional certifications and regulatory requirements, while medical devices and medical diagnostics benefit from AI for biopharma in target identification and AI certification for professional standards.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

Artificial Intelligence (AI) is revolutionizing the drug discovery market by offering innovative solutions to optimize various stages of the drug development lifecycle. From drug structure optimization to clinical trial optimization, AI is transforming the way new drugs are discovered and developed. One of the significant applications of AI in drug discovery is personalized medicine, where it aids in disease prediction and precision medicine. By analyzing gene data and variant data, AI algorithms can identify potential drug targets and predict their efficacy for specific patient populations. AI also plays a crucial role in drug delivery, drug resistance, and drug safety. It assists in optimizing drug delivery systems, identifying potential drug resistance mechanisms, and monitoring drug safety during clinical development.
Moreover, AI is facilitating biomarker discovery, drug disease association, hit compounds identification, and drug repurposing. It analyzes vast amounts of data from biotechnology and healthcare innovation to identify new drug targets and associations between diseases and drugs. The drug discovery platform is also evolving with AI, enabling faster and more efficient drug development.

Additionally, pharmaceutical innovation continues to thrive with AI, as it streamlines the drug development process, enhances drug design, and supports regulatory compliance. The integration of AI in drug manufacturing and clinical development further accelerates the pace of innovation in the healthcare sector. In conclusion, AI is a game-changer in the drug discovery market, offering numerous benefits from drug structure optimization to regulatory compliance. Its applications in personalized medicine, drug delivery, drug resistance, drug safety, biomarker discovery, and drug development lifecycle are transforming the pharmaceutical industry and driving healthcare innovation.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Deployment

  Cloud-based
  On-premises


Therapeutic Area

  Oncology
  Infectious diseases
  Neurology
  Metabolic diseases
  Others


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France


  APAC

    China
    India
    South Korea


  South America



  Middle East and Africa

By Deployment Insights

The cloud-based segment is estimated to witness significant growth during the forecast period.

Artificial Intelligence (AI) plays a crucial role in the drug discovery market, particularly through the application of advanced cloud-based solutions. These technologies offer advantages such as scalability, accessibility, and computational power, enabling companies to accelerate the drug discovery process more effectively. For instance, XtalPi, a global technology company, utilizes AI, quantum physics, and robotics to innovate in life sciences, chemistry, and new materials. By partnering with Amazon Web Services (AWS), XtalPi supports over 150 companies, including 16 of the world's leading pharmaceutical firms, in expediting drug discovery and development. This collaboration underscores the significance of AI in driving innovation and efficiency

According to Cognitive Market Research, the Global AI in patient engagement Market Size will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.

The AI in patient engagement market will expand significantly by XX% CAGR between 2024 and 2031.
The cloud-based delivery type accounts for the largest market share and is anticipated to a healthy growth over the approaching years.
The usage of AI in patient engagement for health tracking and insights holds the largest market share compared to others.
The application of AI in patient engagement in the outpatient segment is the market’s largest contributor and is anticipated to expand at a CAGR of XX% during the projected period.
In the therapeutical area of AI in patient engagement, Chatbots hold the largest market share compared to households.
The usage of AI in patient engagement by payers as end-users holds the largest market share compared to others.
North-America region dominated the market and accounted for the highest revenue of XX% in 2022 and it is projected that it will grow at a CAGR of XX% in the future.

Factors Affecting the Growth of the AI in Patient Engagement Market

Enhanced Patient Engagement and predictive analytical benefits associated with AI operated machines are driving the growth of AI in patient engagement market.

AI-driven technologies are playing a pivotal role in enhancing patient engagement and empowering individuals to take an active role in their healthcare journey. AI with benefits like personalized medical insights, drug reminders, and virtual medical support tools, has fostered seamless communication between patients and healthcare providers to ensure adherence to treatment plans and healthier lifestyles. AI-powered chatbots and mobile applications have made things easier for patients to engage in self-management practices. Furthermore, AI-driver virtual assistants have revolutionized remote monitoring and real-time feedback. AI has now enhanced patient engagement by improving treatment adherence and ensuring better health results.

Another benefit of AI in healthcare includes the power of predictive analytics to detect potential diseases and alarm the patient and service provider before head and necessary steps to be taken to prevent the same. These predictive models can estimate the likelihood of disease onset or progression with impressive accuracy. It is performed by analyzing vast healthcare datasets that encompass patient demographics, medical histories, and environmental factors. The usage and adoption of this model involves AI algorithms identifying individuals at high risk of developing chronic diseases such as diabetes or cardiovascular ailments and guiding precautionary measurements such as changes in existing lifestyles. It can be beneficial to mitigate any serious disease possibility and also reduce healthcare costs linked with hospitalizations. This way AI can help mankind to shift from a reactive to preventive care approach and lifestyle leading to a healthier society and enhanced overall well-being.

All these benefits of AI integration with patient engagement have persuaded the healthcare sector and also patients to lean a little more on machines and their adoption leading a continuous growth in the market.

Data privacy & Security concerns are restraining the growth of the AI in patient-engagement market

These days, Artificial intelligence is prevailing in almost every industry. On average, 94% of healthcare businesses utilize AI or machine learning in some capacity and 83% of healthcare organizations have implemented an artificial intelligence strategy. And almost 60% of United States healthcare executives believe that AI is effective at improving clinical outcomes. However, some physicians and patients have concerns about the privacy and security of the technology because of which users hesitate to use the same. Normally, to train and improve artificial intelligence applications and models,

Approximately, 40% of physicians are concerned about AI’s impact on patient privacy. There is a risk of biases and flawed algorithms, both of which have the potential to create an unsatisfying patient experience. Insufficient handling of data storage may lead to leakage of data allowing unauthorized people to access the data and misuse the same for their benefit. ...

Report of Artificial Intelligence in Diabetes Management Market is covering the summarized study of several factors encouraging the growth of the market such as market size, market type, major regions and end user applications. By using the report customer can recognize the several drivers that impact and govern the market. The report is describing the several types of Artificial Intelligence in Diabetes Management Industry. Factors that are playing the major role for growth of specific type of product category and factors that are motivating the status of the market.

Life Sciences Society and Policy Impact Factor 2024-2025 - ResearchHelpDesk - The purpose of Life Sciences, Society and Policy (LSSP) is to analyze social, ethical and legal dimensions of the most dynamic branches of life sciences and technologies, and to discuss ways to foster responsible innovation, sustainable development, and user-driven social policies. LSSP provides an academic forum for an engaged scholarship at the intersection of life sciences, philosophy, bioethics, science studies, and policy research, and covers a broad area of inquiry both in emerging research areas such as genomics, bioinformatics, biophysics, molecular engineering, nanotechnology, and synthetic biology and in more applied fields such as translational medicine, food science, environmental science, climate studies, research on animals, sustainability, science education, and others. The goal is to produce insights, tools, and recommendations that are relevant not only for academic researchers and teachers, but also for civil society, policymakers, and industry, as well as for professionals in education, health care, and the media, thus contributing to better research practices, better policies, and a more sustainable global society. Established in 2005 as Genomics, Society, and Policy, the journal has gradually expanded its area of research and critical reflection, particularly encouraging interdisciplinary collaboration and now developing along with four main directions: How science and innovation affect society and the environment, and how responsible research can integrate societal needs and concerns in the process of research, with a strong focus on sustainability, responsibility and public engagement Where humanities and science meet: multidisciplinary and interdisciplinary scholarship, for instance on neuro-enhancement and digitalization How research can inform evidence-based practices and policies How philosophical traditions (such as phenomenology, hermeneutics, dialectics, psychoanalysis, pragmatism, and critical theory) can help to understand and address concrete issues of emerging life sciences and technologies. As all the topics in scope and disciplines are addressed from an international and global perspective, the journal welcomes submissions from all countries and regions around the world on a broad range of subjects, including quantitative or qualitative research and case studies. The editors also welcome suggestions for thematic series. Topics addressed through contributions within the journal might include, but will not be restricted to: Human bioethics Societal and cultural relevance of genomics Ethical, legal, and social implications/aspects of emerging sciences (ELSI/ELSA) Responsible research and innovation (RRI) Constructive and interactive technology assessment Sustainability, biodiversity and climate change Neuro-ethics and cognitive enhancement Artificial intelligence and automation Animal bioethics Mental health ethics and policy Sexuality and gender identity Organizational ethics Environmental bioethics Bioethics, world-views, and religion Bioethics and gender Pediatric and family ethics Philosophy of medicine Rural and developmental bioethics Public health ethics Race and culture/ethnicity Reproduction The journal has an international multidisciplinary editorial board with leading academics in the fields of ethics, philosophy, bioethics, social sciences, genomics, political science, sociology, and economics.

Market Overview: The global online journal app market is experiencing steady growth, driven by increasing smartphone and internet penetration, the rising need for self-reflection and emotional well-being, and the popularity of journaling as a therapeutic practice. The market was valued at USD XXX million in 2025 and is projected to reach USD XXX million by 2033, exhibiting a CAGR of XX% from 2025 to 2033. The increasing adoption of personalized mental health apps and the growing awareness of mental health issues are further contributing to market expansion. Market Dynamics: Key trends shaping the market include the integration of artificial intelligence (AI) and machine learning (ML) to analyze journal entries and provide insights, the rise of subscription-based models offering premium features and community support, and the emergence of niche apps catering to specific interests or demographics. However, privacy concerns regarding the storage and use of personal data may restrain market growth. The market is highly competitive, with established players such as Day One, Diarium, and Penzu facing competition from emerging startups with innovative offerings. North America and Europe hold a significant market share, while Asia Pacific is projected to witness the highest growth potential due to increasing internet penetration and disposable income.

American Journal of Pathology Impact Factor 2024-2025 - ResearchHelpDesk - The American Journal of Pathology, official journal of the American Society for Investigative Pathology, published by Elsevier, Inc., seeks high-quality original research reports, reviews, and commentaries related to the molecular and cellular basis of disease. The editors will consider basic, translational, and clinical investigations that directly address mechanisms of pathogenesis or provide a foundation for future mechanistic inquiries. Examples of such foundational investigations include data mining, identification of biomarkers, molecular pathology, and discovery research. Foundational studies that incorporate deep learning and artificial intelligence are also welcome. High priority is given to studies of human disease and relevant experimental models using molecular, cellular, and organismal approaches.

Internet Medical Platform Market Outlook

The global Internet Medical Platform market size was valued at approximately USD 45.2 billion in 2023 and is projected to grow to USD 129.8 billion by 2032, at a remarkable CAGR of 12.5% during the forecast period. The primary growth factor driving this market is the increasing adoption of digital health technologies, spurred by the necessity for remote healthcare solutions and the proliferation of internet connectivity worldwide.

One of the significant growth factors for the Internet Medical Platform market is the increasing prevalence of chronic diseases, which necessitates continuous monitoring and management. With the rise in chronic conditions like diabetes, hypertension, and cardiovascular diseases, there has been a growing demand for platforms that offer remote monitoring and telemedicine services. These platforms allow patients to receive care from the comfort of their homes, reducing the need for frequent hospital visits and minimizing healthcare costs. Additionally, the integration of Artificial Intelligence (AI) and Machine Learning (ML) in these platforms has enhanced their capability to provide accurate and timely medical advice, further driving their adoption.

Another critical driver for this market is the growing emphasis on preventive care and early diagnosis. Internet medical platforms offer tools and services that enable early detection and management of potential health issues before they become severe. This proactive approach not only improves patient outcomes but also reduces the overall burden on healthcare systems. Governments and healthcare organizations across the globe are increasingly investing in digital health initiatives to promote preventive care, which is expected to fuel the growth of the Internet Medical Platform market in the coming years.

The COVID-19 pandemic has significantly accelerated the adoption of internet medical platforms. With lockdowns and social distancing measures in place, traditional healthcare delivery methods faced numerous challenges. This created a surge in demand for telemedicine and online consultation services, as patients sought safe and convenient ways to access healthcare. The pandemic highlighted the importance of digital health solutions in maintaining continuity of care, leading to increased investments and advancements in this sector. The experience gained during the pandemic is expected to have a lasting impact, driving sustained growth in the Internet Medical Platform market.

From a regional perspective, North America currently holds the largest share in the Internet Medical Platform market, driven by advanced healthcare infrastructure and high digital literacy among the population. However, the Asia Pacific region is expected to witness the highest growth rate during the forecast period. Factors such as increasing internet penetration, rising healthcare expenditure, and growing awareness about digital health solutions are contributing to the rapid adoption of these platforms in the region. Governments in countries like China and India are also actively promoting digital health initiatives, further boosting market growth in the Asia Pacific.

Service Type Analysis

The Internet Medical Platform market is segmented by service type into Telemedicine, Online Consultation, E-Pharmacy, Remote Monitoring, and Others. Telemedicine services have gained significant traction in recent years due to their ability to provide remote healthcare services. Telemedicine utilizes telecommunications technology to connect patients with healthcare providers, thereby enhancing access to medical services, especially in remote and underserved areas. The convenience and cost-effectiveness of telemedicine have made it a preferred choice for many patients and healthcare providers, contributing to its dominant position in the market.

Online Consultation services are another critical component of the Internet Medical Platform market. These services enable patients to consult with doctors and specialists via video calls, chat, or email. The demand for online consultations has surged, particularly during the COVID-19 pandemic, as patients sought safe and convenient ways to access healthcare without visiting healthcare facilities. The integration of advanced features like AI-driven symptom checkers and automated appointment scheduling has further enhanced the user experience, driving the growth of online consultation services.

E-Pharmacy services are also gaining popularity, providing patients with the convenience of ordering medications online and h

Unlock valuable biomedical knowledge with our comprehensive PubMed Dataset, designed for researchers, analysts, and healthcare professionals to track medical advancements, explore drug discoveries, and analyze scientific literature.

Dataset Features

Scientific Articles & Abstracts: Access structured data from PubMed, including article titles, abstracts, authors, publication dates, and journal sources. Medical Research & Clinical Studies: Retrieve data on clinical trials, drug research, disease studies, and healthcare innovations. Keywords & MeSH Terms: Extract key medical subject headings (MeSH) and keywords to categorize and analyze research topics. Publication & Citation Data: Track citation counts, journal impact factors, and author affiliations for academic and industry research.

Customizable Subsets for Specific Needs Our PubMed Dataset is fully customizable, allowing you to filter data based on publication date, research category, keywords, or specific journals. Whether you need broad coverage for medical research or focused data for pharmaceutical analysis, we tailor the dataset to your needs.

Popular Use Cases

Pharmaceutical Research & Drug Development: Analyze clinical trial data, drug efficacy studies, and emerging treatments. Medical & Healthcare Intelligence: Track disease outbreaks, healthcare trends, and advancements in medical technology. AI & Machine Learning Applications: Use structured biomedical data to train AI models for predictive analytics, medical diagnosis, and literature summarization. Academic & Scientific Research: Access a vast collection of peer-reviewed studies for literature reviews, meta-analyses, and academic publishing. Regulatory & Compliance Monitoring: Stay updated on medical regulations, FDA approvals, and healthcare policy changes.

Whether you're conducting medical research, analyzing healthcare trends, or developing AI-driven solutions, our PubMed Dataset provides the structured data you need. Get started today and customize your dataset to fit your research objectives.

The Generative Artificial Intelligence (Gen AI) services market is experiencing explosive growth, driven by advancements in deep learning, natural language processing, and computer vision. The market, currently valued at approximately $15 billion in 2025, is projected to achieve a Compound Annual Growth Rate (CAGR) of 35% from 2025 to 2033, reaching an estimated $150 billion by 2033. This robust expansion is fueled by increasing adoption across diverse sectors, including electronic design automation, entertainment (video game development, personalized content creation), and healthcare (drug discovery, personalized medicine). Key application segments like text generation and image generation are currently leading the market, but audio generation and other emerging modalities are rapidly gaining traction. The market’s growth is also being driven by the growing availability of large language models and the decreasing cost of computing power, enabling wider accessibility and deployment of Gen AI solutions. Major technology companies like NVIDIA, Google, and OpenAI are at the forefront of innovation, while consulting firms like McKinsey and Bain & Company are leveraging this technology to offer innovative business solutions. However, several factors could potentially restrain market growth. These include ethical concerns surrounding bias in AI models, data privacy issues, the high cost of implementation and maintenance of Gen AI systems, and the need for specialized skills to develop and deploy these solutions. Furthermore, regulatory uncertainties surrounding the use of AI could impact the speed of adoption. Despite these challenges, the overall outlook for the Gen AI services market remains highly positive. The continued advancements in AI technologies, coupled with increasing demand from diverse industries, are poised to drive significant market expansion over the forecast period. The competition in this dynamic market is fierce, with established tech giants competing with specialized AI service providers and consulting firms. The future success of companies will depend on their ability to innovate, adapt to changing market dynamics, and address the ethical and regulatory considerations associated with Gen AI.